A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

BACKGROUND: Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Ruth E., Kynaston, Howard G., Alhasso, Abdulla A., Duong, Trinh, Paez, Edgar M., Jovic, Gordana, Scrase, Christopher D., Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L., Stone, Michael, Parmar, Mahesh K.B., Abel, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2016
Materias:
Platinum Priority – Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854173/
https://www.ncbi.nlm.nih.gov/pubmed/26707868
http://dx.doi.org/10.1016/j.eururo.2015.11.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854173/
https://www.ncbi.nlm.nih.gov/pubmed/26707868
http://dx.doi.org/10.1016/j.eururo.2015.11.030

Ejemplares similares